Cutler Group’s Cardlytics CDLX Stock Holding History

Cutler Group’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-240	Closed	-$3K	–	4715
2020 Q2	$3K	Buy	+240	New	+$139K	﹤0.01%	3574

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Cutler Group's CDLX Position: Q4 2021 in Review

Cutler Group sold out of Cardlytics (CDLX) in Q4 2021, closing a stake of 10 shares — an estimated $8K sold.

Cutler Group first reported a position in CDLX in Q4 2019 and held it in 7 quarters. The position peaked at $238K in Q4 2020. 163 funds tracked by Wall St. Rank hold CDLX as of Q4 2021.

Cutler Group reported no remaining Cardlytics position as of Q4 2021 after selling out during the quarter.
Cutler Group sold 10 Cardlytics shares in Q4 2021, an estimated $8K.
Cutler Group first reported a position in Cardlytics in Q4 2019 and held it in 7 quarters.
Cutler Group's Cardlytics position peaked at $238K in Q4 2020.
163 funds tracked by Wall St. Rank held Cardlytics as of Q4 2021.

Based on Cutler Group's 13F filing for Q4 2021, filed 18 Jan 2022.